- €189.42m
- €98.76m
- €6.86m
Brief: Transgene Reports Results From Clinical Study Of TG4001 With avelumab
Brief: Transgene And Hypertrust Patient Data Care Announce Blockchain Solution For Clinical Trials Of Personalized Healthcare
Brief: Transgene’s, Bioinvent’s BT-001 Achieves High Tumor Cure Rates In Preclinical Models
Brief: Transgene: New Data From Next-Generation Immunotherapy Platforms
Brief: Transgene Reduces Nominal Value To 0.50 From 1 Euro Per Share
Brief: Transgene Says Data Confirms High Accuracy Of Cancer Vaccine TG4050
Brief: Transgene Q1 Operating Revenue Up At 3.0 Million Euros
Brief: Vaxxel Acquires Transgene's DuckCelt-T17 Cell Line
Brief: Transgene Says Coronavirus Crisis Might Impact Level Of Revenues From Collaborations
Brief: Transgene And BioInvent To Present Data On BT-001
Brief: Transgene: First Patient Dosed With Oncolytic Virus TG6002
Brief: Transgene And NEC Start Two Clinical Trials With TG4050
Brief: Transgene Reports On Combination Trial Of TG4010, Chemotherapy And Nivolumab
Brief: Transgene And BioInvent Announce Preclinical Data For BT-001
Brief: Transgene Q3 Operating Income Down At 3.8 Million Euros
Brief: Transgene Reports Promising Efficacy Results With TG4001 In Combination With Avelumab
Brief: Transgene H1 Operating Revenues Amounted To 4.9 Million Euros
Brief: Transgene Receives Approval From ANSM To Initiate Two Clinical Trials
Brief: Transgene Updates On Phocus Study Of Pexa-Vec In Liver Cancer